Title: Bisi JE, et al. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors. Oncotarget. 2017 Jun 27;8(26):42343-42358.
1628256-23-4
1374639-75-4
1211441-98-3
1211443-80-9
1374639-79-8
1328934-40-2
1379604-65-5 | 5-(3-(2-(2-methoxyphenyl)acetyl)-1H-indol-1-yl)pentanoicacid | AA01EOUC
1800101-60-3 | N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(5-fluoropentyl)-1H-indazole-3-carboxamide | AA01EP2F | MFCD24368589
220556-74-1 | N-[(1R)-2-hydroxy-1-methylethyl]-9Z,12Z-octadecadienamide | AA01EPCX
897613-29-5 | N1-(3-acetamidophenyl)-N2-(2-(4-methyl-2-(p-tolyl)thiazol-5-yl)ethyl)oxalamide | AA01EPJI | MFCD07644661
101365-59-7 | 2-methoxy-N-phenyl-N-4-piperidinyl-acetamide,monohydrochloride | AA01EPP1
958001-92-8 | N-acetyl-L-α-aspartyl-L-asparaginyl-L-leucyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-L-α-asparagine | AA01EPVS
91021-66-8 | (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16-[(1S,2R,3S)-3-[(2R,4R,5S,6R)-4-[(6-deoxy-2-O-methyl-α-L-mannopyranosyl)oxy]tetrahydro-2-hydroxy-5-methyl-6-(1-methylethyl)-2H-pyran-2-yl]-2-hydroxy-1-methylbutyl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-oxacyclohexadeca-3,5,11,13-tetraen-2-one | AA01EQ5E | MFCD28899136
93503-09-4 | Aminotetralinehydrochloride,(S)-(-)-7-Methoxy-N-propyl-2- | AA01EQBW | MFCD10567065
113515-44-9 | 1-(2-{[2-(4-Chlorophenoxy)acetyl]oxy}ethyl)-2,4,6-trimethylpyridin-1-ium perchlorate | AA01EQOS | MFCD00964186
127236-78-6 | 1-(1H-1,2,3-Benzotriazol-1-ylmethyl)-1-methylpyrrolidin-1-ium iodide | AA01ERJK | MFCD00958608